{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:02:47Z","timestamp":1789506167186,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22077115"],"award-info":[{"award-number":["22077115"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104231"],"award-info":[{"award-number":["82104231"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008582","name":"McGill University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["JH2022-1-079"],"award-info":[{"award-number":["JH2022-1-079"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7232138"],"award-info":[{"award-number":["7232138"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["JH2023-1-092"],"award-info":[{"award-number":["JH2023-1-092"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118259","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T08:03:11Z","timestamp":1760428991000},"page":"118259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Development of dual AR\/ARV7 degraders with 3,5-dimethylisoxazole to overcome antiandrogen resistance in castration-resistant prostate cancer"],"prefix":"10.1016","volume":"301","author":[{"given":"Rongyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojia","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1610-5061","authenticated-orcid":false,"given":"Jinming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118259_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"Ca - Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2025.118259_bib2","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1080\/14656566.2018.1527312","article-title":"Advancing therapies in metastatic castration-resistant prostate cancer","volume":"19","author":"Baciarello","year":"2018","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.118259_bib3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.eururo.2013.08.008","article-title":"Castration-resistant prostate cancer: from new pathophysiology to new treatment","volume":"65","author":"Sridhar","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejmech.2025.118259_bib4","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030452","article-title":"Androgen signaling in prostate cancer","volume":"7","author":"Dai","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ejmech.2025.118259_bib5","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.eururo.2014.05.038","article-title":"Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial","volume":"66","author":"Attard","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejmech.2025.118259_bib6","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.cell.2013.07.029","article-title":"A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer","volume":"154","author":"Chang","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.118259_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12672-014-0177-y","article-title":"The link between androgen receptor splice variants and castration-resistant prostate cancer","volume":"5","author":"Sprenger","year":"2014","journal-title":"Hormones Cancer"},{"key":"10.1016\/j.ejmech.2025.118259_bib8","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1073\/pnas.0500381102","article-title":"Structural basis for antagonism and resistance of bicalutamide in prostate cancer","volume":"102","author":"Bohl","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2025.118259_bib9","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s13277-011-0209-y","article-title":"Androgen receptor W741C and T877A mutations in AIDL cells, an androgen-independent subline of prostate cancer LNCaP cells","volume":"32","author":"Otsuka","year":"2011","journal-title":"Tumour Biol. : J. Int. Soc. Oncodev. Biol. Med."},{"key":"10.1016\/j.ejmech.2025.118259_bib10","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1158\/1535-7163.MCT-05-0124","article-title":"Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers","volume":"4","author":"Dong","year":"2005","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.118259_bib11","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00499","article-title":"Overcoming mutation-based resistance to antiandrogens with rational drug design","volume":"2","author":"Balbas","year":"2013","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2025.118259_bib12","doi-asserted-by":"crossref","first-page":"12496","DOI":"10.3390\/ijms140612496","article-title":"Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer","volume":"14","author":"Lallous","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118259_bib13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ccr.2010.04.027","article-title":"Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor","volume":"17","author":"Andersen","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.118259_bib14","doi-asserted-by":"crossref","first-page":"26417","DOI":"10.1074\/jbc.M114.553818","article-title":"Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer","volume":"289","author":"Dalal","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118259_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117212","article-title":"Recent advances in developing targeted protein degraders","volume":"284","author":"Cheng","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118259_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118259_bib17","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.1021\/acs.jmedchem.3c00585","article-title":"Discovery of BWA-522, a first-in-class and orally bioavailable PROTAC degrader of the androgen receptor targeting N-Terminal domain for the treatment of prostate cancer","volume":"66","author":"Zhang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118259_bib18","doi-asserted-by":"crossref","first-page":"14277","DOI":"10.1021\/acs.jmedchem.4c01104","article-title":"Radioactive ADME demonstrates ARV-110's high druggability despite low oral bioavailability","volume":"67","author":"He","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118259_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-020-00924-z","article-title":"Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies","volume":"13","author":"He","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118259_bib20","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.1158\/0008-5472.CAN-17-0976","article-title":"Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer","volume":"77","author":"Ponnusamy","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118259_bib21","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1158\/1078-0432.CCR-19-1458","article-title":"Potential next-generation therapeutic for enzalutamide-resistant prostate cancer","volume":"25","author":"Ponnusamy","year":"2019","journal-title":"Clin. Cancer Res.: off. J. Am. Associate. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118259_bib22","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/acs.jmedchem.8b00973","article-title":"New generation of selective androgen receptor degraders: our initial design, synthesis, and biological evaluation of new compounds with enzalutamide-resistant prostate cancer activity","volume":"62","author":"Hwang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118259_bib23","doi-asserted-by":"crossref","first-page":"11045","DOI":"10.1021\/acs.jmedchem.1c00439","article-title":"Exploration and biological evaluation of basic heteromonocyclic propanamide derivatives as SARDs for the treatment of enzalutamide-resistant prostate cancer","volume":"64","author":"He","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118259_bib24","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.1021\/acs.jmedchem.3c02177","article-title":"Structure-activity relationship (SAR) studies of novel monovalent AR\/AR-V7 dual degraders with potent efficacy against advanced prostate cancer","volume":"67","author":"Xiao","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118259_bib25","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1021\/jm020576u","article-title":"Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy","volume":"46","author":"Clement","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118259_bib26","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1158\/1535-7163.MCT-08-0230","article-title":"Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase\/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer","volume":"7","author":"Vasaitis","year":"2008","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.118259_bib27","doi-asserted-by":"crossref","first-page":"27440","DOI":"10.18632\/oncotarget.4578","article-title":"Galeterone and VNPT55 induce proteasomal degradation of AR\/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo","volume":"6","author":"Kwegyir-Afful","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.118259_bib28","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1021\/jm400048v","article-title":"Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer","volume":"56","author":"Purushottamachar","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118259_bib29","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1021\/acsmedchemlett.6b00137","article-title":"Identification of novel steroidal androgen receptor degrading agents inspired by galeterone 3\u03b2-Imidazole carbamate","volume":"7","author":"Purushottamachar","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118259_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2023.109184","article-title":"Murine toxicology and pharmacokinetics of lead next generation galeterone analog, VNPP433-3\u03b2","volume":"192","author":"Thomas","year":"2023","journal-title":"Steroids"},{"key":"10.1016\/j.ejmech.2025.118259_bib31","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.70700","article-title":"Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer","volume":"12","author":"Wu","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2025.118259_bib32","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1021\/acs.jmedchem.3c01668","article-title":"Design and synthesis of dual-target inhibitors targeting androgen receptors and glucocorticoid receptors to overcome antiandrogen resistance in castration-resistant prostate cancer","volume":"67","author":"Li","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118259_bib33","first-page":"1","article-title":"In silico study of androgen receptor N-terminal domain and exploration of its modulators","author":"Zhang","year":"2024","journal-title":"J. Biomol. Struct. Dynam."},{"key":"10.1016\/j.ejmech.2025.118259_bib34","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41585-021-00438-4","article-title":"Resistance to second-generation androgen receptor antagonists in prostate cancer","volume":"18","author":"Schmidt","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.ejmech.2025.118259_bib35","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118259_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115077","article-title":"Targeting the N-terminal domain of the androgen receptor: the effective approach in therapy of CRPC","volume":"247","author":"Ji","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118259_bib37","doi-asserted-by":"crossref","first-page":"8330","DOI":"10.1021\/acs.jmedchem.4c03043","article-title":"Discovery of novel bifunctional agents as potent androgen receptor antagonists and degraders for the treatment of enzalutamide-resistant prostate cancer","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425010244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425010244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:03:59Z","timestamp":1773147839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425010244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":37,"alternative-id":["S0223523425010244"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118259","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of dual AR\/ARV7 degraders with 3,5-dimethylisoxazole to overcome antiandrogen resistance in castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118259","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118259"}}